Zach Bornholdt, PhD is a co-founder of Eitr and serves as Chief Executive Officer. Prior to founding Eitr, Zach was the Senior Director of Antibody Discovery & Research at Mapp Biopharmaceutical, where he led the discovery and early development efforts for MBP134, a pan-ebolavirus immunotherapeutic now in Phase I clinical trials. Zach was also an Assistant Professor of Virology at The Scripps Research Institute. Zach holds a BS in Microbiology from UC Davis and a PhD in Molecular Virology and Microbiology from Baylor College of Medicine.

Crystal Moyer, PhD is a co-founder of Eitr and serves as the company's Chief Scientific Officer. Before founding Eitr, she worked at Mapp Biopharmaceutical where she led a team of researchers in the development and implementation of platform technologies for antibody discovery and research. Crystal also successfully managed laboratory operations in a competitive biopharmaceutical environment and served as Principal Investigator or Technical Lead for multiple antibody programs. Crystal received a BS in Biology from the University of Pittsburgh and a PhD in Biology from The Scripps Research Institute.

Kartik Chandran, PhD is a co-founder of Eitr. He is a professor of Microbiology & Immunology, the Gertrude and David Feinson Chair of Medicine and the Harold and Muriel Faculty Scholar in Virology at Albert Einstein College of Medicine. Kartik’s group uncovers and investigates the interactions between emerging viruses and their hosts and exploits them to develop antiviral countermeasures. Their key discoveries include critical entry receptors exploited by Ebola virus and Sin Nombre virus, and the pan-ebolavirus antibody cocktail MBP-134. Kartik also leads Prometheus, an international consortium funded by the NIH that is discovering human antibody-based therapeutics against lethal emerging bunyaviruses.